Both companies will provide healthcare professionals with information on the drug
Eli Lilly Japan and Daiichi Sankyo have entered into a collaborative agreement to commercialise Lasmiditan Succinate in Japan for the acute treatment of migraines. Eli Lilly Japan has submitted a new drug application for the treatment of migraines. Under the terms of the agreement, Eli Lilly Japan will hold authorisation for marketing lasmiditan succinate, similar to the humanised anti-CGRP monoclonal antibody Emgality (generic name: galcanezumab (genetic recombination)) to which a sales agreement has already been concluded between the two companies, and Daiichi Sankyo will take charge of its distribution and sales after marketing approval. Both companies will provide healthcare professionals with information on the drug.
Through this commercialisation collaboration with Daiichi Sankyo, which has a solid operating foundation in Japan based on its established position and global network in the fields of central nervous system diseases and pain management, Eli Lilly Japan will strengthen its system for providing healthcare professionals with proper information through both Emgality and lasmiditan succinate after obtaining marketing approval.
Daiichi Sankyo will make efforts to improve the quality of life for many more patients with migraines by providing total care support through Emgality as a prophylaxis of migraine attacks and lasmiditan succinate.
